Atrasentan for the treatment of diabetic nephropathy

References

• Wild S, Roglic G, Green G, et al. Global prevalence of diabetes: estimates for the year 2000 and projections for 2030. Diabetes Care. 2004;27:1047–1053.
   PubMed Web of Science ®Google Scholar
• American Diabetes Association. Standards of medical care in diabetes—2014. Diabetes Care. 2014;37(Suppl. 1):S14–S80.
   PubMed Web of Science ®Google Scholar
• Fernandez-Fernandez B, Ortiz A, Gomez-Guerrero C, et al.. Therapeutic approaches to diabetic nephropathy–beyond the RAS. Nat Rev Nephrol. 2014;10:325–346.
   PubMed Web of Science ®Google Scholar
• Yanagisawa M, Kurihara H, Kimura S, et al.. A novel potent vasoconstrictor peptide produced by vascular endothelial cells. Nature. 1998;332:411–415.
   Web of Science ®Google Scholar
• Davenport AP, Hyndman KA, Dhaun N, et al.. Endothelin. Pharmacol Rev. 2016;68:357–418.
   PubMed Web of Science ®Google Scholar
• Inscho EW, Imig JD, Cook AK, et al. ETA and ETB receptors differentially modulate afferent and efferent arteriolar responses to endothelin. Br J Pharmacol. 2005;146:1019–1026.
   PubMed Web of Science ®Google Scholar
• Benz K, Amann K. Endothelin in diabetic renal disease. Contrib Nephrol. 2011;172:139–148.
   PubMed Web of Science ®Google Scholar
• Kohan DE, Inscho EW, Wesson D, et al.. Physiology of endothelin and the kidney. Comp Physiol. 2011;1:883–919.
   PubMed Web of Science ®Google Scholar
• Barton M, Sorokin A. Endothelin and the Glomerulus in Chronic Kidney Disease. SeminNephrol. 2015;35:156–167.
   Web of Science ®Google Scholar
• Guan Z, Inscho EW. Endothelin and the renal vasculature. Contrib Nephrol. 2011;172:35–49.
   PubMed Web of Science ®Google Scholar
• Tobe S, Kohan DE, Singarayer R. Endothelin Receptor Antagonists: New Hope for Renal Protection?. Curr Hypertens Rep. 2015;17:57.
   PubMed Web of Science ®Google Scholar
• Kohan DE, Pritchett Y, Molitch M, et al.. Addition of atrasentan to renin-angiotensin system blockade reduces albuminuria in diabetic nephropathy. J Am Soc Nephrol. 2011;22:763–772.
   PubMed Web of Science ®Google Scholar
• Kohan DE, Pollock DM. Endothelin antagonists for diabetic and non-diabetic chronic kidneydisease. Br J Clin Pharmacol. 2013;76:573–579. 32.
   PubMed Web of Science ®Google Scholar
• Andress DL, Coll B, Pritchett Y, et al. Clinical efficacy of the selective endothelin A receptor antagonist, atrasentan, in patients with diabetes and chronic kidney disease (CKD). LifeSci. 2012;15:739–742.
   Web of Science ®Google Scholar
• Anguiano L, Riera M, Pascual J, et al. Endothelin Blockade in Diabetic Kidney Disease. J Clin Med. 2015;4:1171–1192.
   PubMed Web of Science ®Google Scholar
• Study of diabetic nephropathy with atrasentan (SONAR). www.clinicaltrials.gov. ( NCT01858532).
   Google Scholar
• Saleh MA, Pollock JS, Pollock DM. Distinct actions of endothelin A-selective versus combined endothelin A/B receptor antagonists in early diabetic kidney disease. J Pharmacol ExpTher. 2011;338:263–270.
   PubMed Web of Science ®Google Scholar
• De Miguel C, Speed JS, Kasztan M, et al. .Endothelin-1 and the kidney: new perspectives and recent findings. Curr Opin Nephrol Hypertens. 2016;25:35–41.
   PubMed Web of Science ®Google Scholar
• De Miguel C, Pollock DM, Pollock JS. Endothelium-derived ET-1 and the development of renal injury. Am J Physiol Regul Integr Comp Physiol. 2015;309:R1071–3.
   Google Scholar
• Buelli S, Rosanò L, Gagliardini E, et al. β-arrestin-1 drives endothelin-1-mediated podocyte activation and sustains renal injury. J Am Soc Nephrol. 2014;25:523–533.
   PubMed Web of Science ®Google Scholar
• Suzuki Y, Lopez-Franco O, Gomez-Garre D, et al. Renal tubulointerstitial damage caused by persistent proteinuria is attenuated in AT1-deficient mice: role of endothelin-1. Am J Pathol. 2001;159:1895–1904.
   PubMed Web of Science ®Google Scholar
• Taniguchi M, Yoshida H. Endoplasmic reticulum stress in kidney function and disease. Curr Opin Nephrol Hypertens. 2015;24:345–350.
   PubMed Web of Science ®Google Scholar
• Hu MC, Kuro-O M, Moe OW. Klotho and kidney disease. J Nephrol. 2010;16:S136–144.
   Google Scholar
• Kuro-O M. Klotho in health and disease. Curr OpinNephrol Hypertens. 2012;21:362–368.
   PubMed Web of Science ®Google Scholar
• Kim SS, Song SH, Kim IJ, et al. .Decreased plasma α-Klotho predict progression of nephropathy with type 2 diabetic patients. J Diabetes Complications. 2016;30:887–892.
   PubMed Web of Science ®Google Scholar
• Kang WL, Xu GS. Atrasentan increased the expression of klotho by mediating miR-199b-5p and prevented renal tubular injury in diabetic nephropathy. Sci Rep. 2016;6:19979.
   PubMed Web of Science ®Google Scholar
• Largo R, Gómez-Garre D, Liu XH, et al. Endothelin-1 upregulation in the kidney of uninephrectomized spontaneously hypertensive rats and its modification by the angiotensin-converting enzyme inhibitor quinapril. Hypertension. 1997;29:1178–1185.
   PubMed Web of Science ®Google Scholar
• Gómez-Garre D, Largo R, Tejera N, et al.. .Activation of NF-kappaB in tubular epithelial cells of rats with intense proteinuria: role of angiotensin II and endothelin-1. Hypertension. 2001;37:1171–1178.
   PubMed Web of Science ®Google Scholar
• Zoja C, Benigni A, Remuzzi G. Cellular responses to protein overload: key event in renal disease progression. Curr Opin Nephrol Hypertens. 2004;13:31–37.
   PubMed Web of Science ®Google Scholar
• Dufek B, Meehan DT, Delimont D, et al. Endothelin A receptor activation on mesangial cells initiates Alport glomerular disease. Kidney Int. 2016;90:300–310.
   PubMed Web of Science ®Google Scholar
• Mann JFE, Green D, Jamerson K, et al.. for the ASCEND Study Group Avosentan. Avosentan for Overt Diabetic Nephropathy. J Am Soc Nephrol. 2010;21:527–535.
   PubMed Web of Science ®Google Scholar
• Rabelink TJ, Kohan DE. Endothelin receptor blockade in patients with diabetic nephropathy. Contrib Nephrol. 2011;172:235–242.
   PubMed Web of Science ®Google Scholar
• Ritz E, Wenzel RR. Endothelin antagonist as add-on treatment for proteinuria in diabetic nephropathy: is there light at the end of the tunnel?. J Am Soc Nephrol. 2011;22:593–595.
   PubMed Web of Science ®Google Scholar
• Czopek A, Moorhouse R, Webb DJ, et al. Therapeutic potential of endothelin receptor antagonism in kidney disease. Am J Physiol Regul Integr Comp Physiol. 2016;310:R388–97.
   Google Scholar
• Gómez-Garre D, Largo R, Liu XH, et al.. .An orally active ETA/ETB receptor antagonist ameliorates proteinuria and glomerular lesions in rats with proliferative nephritis. Kidney Int. 1996;50:962–972.
   PubMed Web of Science ®Google Scholar
• Hocher B, Schwarz A, Reinbacher D, et al. Effects of endothelin receptor antagonists on the progression of diabetic nephropathy. Nephron. 2001;87:161–169.
   PubMed Web of Science ®Google Scholar
• deZeeuw D, Coll B, Andress D, et al. The endothelin antagonist atrasentan lowers residual albuminuria in patients with type 2 diabetic nephropathy. J Am Soc Nephrol. 2014;25:1083–1093.
   PubMed Web of Science ®Google Scholar
• Tan RJ, Zhou L, Zhou D, et al. Endothelin receptor a blockade is an ineffective treatment for adriamycin nephropathy. PLoS One. 2013;8:e79963.
   Google Scholar
• Saleh MA, Boesen EI, Pollock JS, et al. Endothelin-1 increases glomerular permeability and inflammation independent of blood pressure in the rat. Hypertension. 2010;56:942–949.
   PubMed Web of Science ®Google Scholar
• Saleh MA, Boesen EI, Pollock JS, et al. .Endothelin receptor A-specific stimulation of glomerular inflammation and injury in a streptozotocin-induced rat model of diabetes. Diabetologia. 2011;54:979–988.
   PubMed Web of Science ®Google Scholar
• Gutierrez S, Palacios I, Egido J, et al. Endothelin-1 induces loss of proteoglycans and enhances fibronectin and collagen production in cultured rabbit synovial cells. Eur J Pharmacol. 1996;302:191–197.
   PubMed Web of Science ®Google Scholar
• Dane MJ, Van Den Berg BM, Avramut MC, et al. Glomerular Endothelial Surface Layer Acts as a Barrier against Albumin Filtration. Am J Pathol. 2013;182:1532–1540.
   PubMed Web of Science ®Google Scholar
• Boels MG, Avramut MC, Koudijs A, et al.. Atrasentan Reduces Albuminuria by Restoring the Glomerular Endothelial Glycocalyx Barrier in Diabetic Nephropathy. Diabetes. 2016;65:2429–2439.
   PubMed Web of Science ®Google Scholar
• Sasser JM, Sullivan JC, Hobbs JL, et al.. Endothelin A receptor blockade reduces diabetic renal injury via an anti-inflammatory mechanism. J Am Soc Nephrol. 2007;18:143–154.
   PubMed Web of Science ®Google Scholar
• Maguire JJ, Davenport AP. Endothelin Receptors and Their Antagonists. Semin Nephrol. 2015;35:125–136.
   PubMed Web of Science ®Google Scholar
• Gómez-Garre D, Guerra M, González E, et al. Aggregation of human polymorphonuclear leukocytes by endothelin: role of platelet-activating factor. Eur J Pharmacol. 1992;224:167–172.
   PubMed Web of Science ®Google Scholar
• López Farré A, Riesco A, Espinosa G, et al. Effect of endothelin-1 on neutrophil adhesion to endothelial cells and perfused heart. Circulation. 1993;88:1166–1171.
   PubMed Web of Science ®Google Scholar
• Molero L, Farré J, García-Mendez A, et al. Endothelin-1 induced proinflammatory markers in the myocardium and leukocytes of guinea-pigs: role of glycoprotein IIB/IIIA receptors. Cardiovasc Res. 2003;57:109–118.
   PubMed Web of Science ®Google Scholar
• Elisa T, Antonio P, Giuseppe P, et al. Endothelin Receptors Expressed by Immune Cells Are Involved in Modulation of Inflammation and in Fibrosis: Relevance to the Pathogenesis of Systemic Sclerosis. J Immunol Res. 2015;2015:147616.
   PubMed Web of Science ®Google Scholar
• McKenna S, Gossling M, Bugarini A, et al. Endotoxemia Induces IκBβ/NF-κB-Dependent Endothelin-1 Expression in Hepatic Macrophages. J Immunol. 2015;195:3866–3879.
   PubMed Web of Science ®Google Scholar
• Hills CE, Squires PE. The role of TGF-β and epithelial-to mesenchymal transition in diabetic nephropathy. CytokineGrowth Factor Rev. 2011;22:131–139.
   PubMed Web of Science ®Google Scholar
• Garud MS, Kulkarni YA. Hyperglycemia to nephropathy via transforming growth factor beta. Curr Diabetes Rev. 2014;10:182–189.
   PubMedGoogle Scholar
• Chang AS, Hathaway CK, Smithies O, et al. Transforming growth factor β1 and diabetic nephropathy. Am J Physiol Renal Physiol. 2016;310:F689–F696.
   Web of Science ®Google Scholar
• Hathaway CK, Gasim AM, Grant R, et al. Low TGFβ1 expression prevents and high expression exacerbates diabetic nephropathy in mice. Proc Natl Acad Sci U S A. 2015;112:5815–5820.
   PubMed Web of Science ®Google Scholar
• Rodriguez-Vita J, Ruiz-Ortega M, Rupérez M, et al.. Endothelin-1, via ETA receptor and independently of transforming growth factor-beta, increases the connective tissue growth factor in vascular smooth muscle cells. Circ Res. 2005;97:125–134.
   PubMed Web of Science ®Google Scholar
• Rupérez M, Lorenzo O, Blanco-Colio LM, et al. Connective tissue growth factor is a mediator of angiotensin II-induced fibrosis. Circulation. 2003;108:1499–1505.
   PubMed Web of Science ®Google Scholar
• Leask A. Targeting the TGFbeta, endothelin-1 and CCN2 axis to combat fibrosis in scleroderma. Cell Signal. 2008;20:1409–1414.
   PubMed Web of Science ®Google Scholar
• Rodrigues-Díez R, Rodrigues-Díez RR, Rayego-Mateos S, et al. The C-terminal module IV of connective tissue growth factor is a novel immune modulator of the Th17 response. Lab Invest. 2013;93:812–824.
   PubMed Web of Science ®Google Scholar
• Rodrigues-Diez RR, Garcia-Redondo AB, Orejudo M, et al. The C-terminal module IV of connective tissue growth factor, through EGFR/Nox1 signaling, activates the NF-κB pathway and proinflammatory factors in vascular smooth muscle cells. Antioxid Redox Signal. 2015;22:29–47.
   PubMed Web of Science ®Google Scholar
• Mather KJ. The vascular endothelium in diabetes–a therapeutic target?. Rev Endocr Metab Disord. 2013;14:87–99.
   PubMed Web of Science ®Google Scholar
• Chou JC, Rollins SD, Ye M, et al. Endothelin receptor-Antagonist attenuates retinal vascular and neuroretinal pathology in diabetic mice. Invest Ophthalmol Vis Sci. 2014;55:2516–2525.
   PubMed Web of Science ®Google Scholar
• Yoon MH, Reriani M, Mario G, et al. Long-term endothelin receptor antagonism attenuates coronary plaque progression in patients with early atherosclerosis. Int J Cardiol. 2013;168:1316–1321.
   PubMed Web of Science ®Google Scholar
• Vatter H, Seifert V. Ambrisentan, a non-peptide endothelin receptor antagonist. Cardiovasc Drug Rev. 2006;24:63–76.
   PubMed Web of Science ®Google Scholar
• Dhaun N, MacIntyre LM, Kerr D, et al. Selective endothelin-A receptor antagonism reduces proteinuria, blood pressure, and arterial stiffness in chronic proteinuric kidney disease. Hypertension. 2011;57:772–779.
   PubMed Web of Science ®Google Scholar
• Weber MA, Black H, Bakris G, et al. A selective endothelin-receptor antagonist to reduce blood pressure in patients with treatment-resistant hypertension: a randomised, double-blind, placebo-controlled trial. Lancet. 2009;374:1423–1431.
   PubMed Web of Science ®Google Scholar
• Wenzel RR, Littke T, Kuranoff S, et al. The endothelin antagonist avosentan reduces albumin excretion rate in diabetic patients with macroalbuminuria: A randomized, placebo-controlled, double-blind trial. J Am Soc Nephrol. 2009;20:655–664.
   PubMed Web of Science ®Google Scholar
• Kohan DE, LambersHeerspink HJ, Coll B, et al. Predictors of Atrasentan-Associated Fluid Retention and Change in Albuminuria in Patients with Diabetic Nephropathy. Clin J Am SocNephrol. 2015;10:1568–1574.
   PubMed Web of Science ®Google Scholar
• Safdar Z. Effect of transition from sitaxsentan to ambrisentan in pulmonary arterial hypertension. Vasc Health Risk Manag. 2011;7:119–124.
   PubMedGoogle Scholar
• Macías Saint-Gerons D, De La Fuente Honrubia C, Montero Corominas D, et al. Hepatotoxicity in patients treated with endothelin receptor antagonists: systematic review and meta-analysis of randomized clinical trials. Med Clin (Barc). 2014;142:333–342.
   PubMed Web of Science ®Google Scholar
• Komers R, Plotkin H. Dual inhibition of renin-angiotensin-aldosterone system and endothelin-1 in treatment of chronic kidney disease. Am J Physiol Regul Integr Comp Physiol. 2016;310:R877–84.
   PubMed Web of Science ®Google Scholar
• Kowala MC, Murugesan N, Tellew J, et al. Novel dual action AT1 and ETA receptor antagonists reduce blood pressure in experimental hypertension. J Pharmacol Exp Ther. 2004;309:275–284.
   PubMed Web of Science ®Google Scholar